Tiziana Life Sciences (Nasdaq: TLSA) Triggers 18 Bullish Signals Following Breakthrough News

*Sponsored Krypton Street Announces Tiziana Life Sciences (Nasdaq: TLSA) As Its Next Potential Breakout Idea! And Here’s Why… Neurodegenerative Market to Double: Projected to grow from $52B in 2024 to over $102B by 2034, highlighting demand for treatments like Foralumab. Bullish Signals Detected: Tiziana Life Sciences (Nasdaq: TLSA) triggered 17 Bullish Signals on TradingView yesterday, potentially reflecting a growing public interest. Breakthrough Intranasal Therapy: Foralumab stands out as the only fully human anti-CD3 antibody delivered intranasally, offering precision and reduced side effects. Top Institutions Join SPMS Trials: Yale, Johns Hopkins, and Cornell now part of Phase 2 trials, boosting credibility for Foralumab in tackling SPMS. Alzheimer’s Research Milestone: First patient with moderate Alzheimer’s dosed at Brigham and Women’s Hospital, advancing critical research efforts. Find out why (TLSA) has jumped to the top of our must-watch list… January 23, 2025 Dear Reader, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) just cranked up the heat with 18 Bullish Signals on TradingView’s 15-minute analysis. Momentum is doing its thing. In a statement today, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) announced it will not pursue immediate capital raising activities, signaling confidence in its path ahead.  This announcement comes on the heels of yesterday’s news of a major breakthrough in MS research.  Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) identified key immune biomarkers in patients treated with nasal Foralumab, highlighting its impact on critical pathways like Tregs and memory T cells.  These discoveries align with prior clinical data showing reduced brain inflammation and were praised by experts as a game-changing step toward personalized treatment strategies. Imagine a future where treating devastating diseases no longer relies on needles or pills, but on a groundbreaking delivery system that’s rewriting the rules of medicine. Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) isn’t just imagining this—they’re making it happen. Just yesterday, Tiziana Life Sciences (Nasdaq: TLSA) triggered 17 Bullish Signals on TradingView’s technical indicator tool using the 30-minute time frame, reflecting growing momentum. This clinical-stage biopharmaceutical company is pioneering transformational dr-ug delivery technologies, poised to reshape the landscape of immunotherapy as we know it. Their efforts come at a pivotal moment.  The global neurodegenerative disease market is forecasted to grow from $52B in 2024 to over $102B by 2034, driven by an aging population, advancements in precision medicine, and a growing need for effective therapies to combat conditions like Alzheimer’s, Parkinson’s, and multiple sclerosis. And according to Benzinga, insiders own over 72% of the company’s shares—what do they know? Could it be the groundbreaking potential of their intranasal therapy, the rapidly growing neurodegenerative disease market, or the promising results from their recent clinical trials? Tiziana Life Sciences, Ltd. (Nasdaq: TLSA)’s focus on intranasal Foralumab places it in a strong position to address these urgent and rapidly expanding needs. At the forefront of their pipeline is intranasal foralumab, the only fully human anti-CD3 monoclonal antibody currently in clinical development.  With the potential to improve efficacy, safety, and tolerability compared to traditional intravenous treatments, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is turning heads for all the right reasons. Let’s explore what sets this company apart. Recent Developments Promising Results for Metabolic Disorders Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) announced findings that its nasal anti-CD3 therapy mitigates side effects commonly associated with GLP-1 agonist discontinuation, such as muscle loss and bone density issues. This development highlights the potential of nasal anti-CD3 in sustaining tissue homeostasis and improving patient outcomes in metabolic and age-related diseases. Foralumab Featured in Nature Reviews Neurology A review article published in Nature Reviews Neurology highlighted Foralumab’s therapeutic potential across multiple neurodegenerative diseases, including Alzheimer’s, multiple sclerosis, ALS, and Parkinson’s. The publication underscored the role of intranasal delivery in dampening microglial activation—a critical factor in disease progression. Alzheimer’s Clinical Trial Milestone Achieved The company dosed its first patient with moderate Alzheimer’s disease using intranasal Foralumab at Brigham and Women’s Hospital in Boston. This innovative therapy targets neuroinflammation by modulating microglial cells, a novel approach distinct from amyloid and tau protein-focused therapies. Expansion of SPMS Clinical Trial to Prestigious Institutions Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) recently expanded its Phase 2 clinical trial for non-active secondary progressive multiple sclerosis (SPMS) to include leading U.S. medical institutions such as Yale University, Johns Hopkins University, and Cornell University. The expanded trial reflects Tiziana’s commitment to advancing research in SPMS, a condition with no FDA-approved therapeutic options. The use of a centralized PET imaging site ensures data consistency and robust trial outcomes. These updates showcase Tiziana Life Sciences, Ltd. (Nasdaq: TLSA)’s relentless focus on addressing significant unmet medical needs with groundbreaking solutions. Redefining Treatment with Intranasal Foralumab At the heart of Tiziana’s efforts is Foralumab, the only fully human anti-CD3 monoclonal antibody currently in clinical trials. Administered intranasally, this therapy doesn’t just break the mold—it demolishes it. This innovative delivery system allows Foralumab to modulate the immune system efficiently while crossing the blood-brain barrier to target neuroinflammation directly. The potential benefits span multiple conditions: Secondary Progressive Multiple Sclerosis (SPMS): Characterized by a progressive loss of neurological function, SPMS remains one of the most challenging forms of multiple sclerosis to address. Alzheimer’s Disease (AD): By modulating microglial activity—key drivers of neuroinflammation—Foralumab offers a fresh approach distinct from conventional amyloid-targeting treatments. The Focus on Neuroinflammatory and Neurodegenerative Conditions Tiziana has zeroed in on areas with substantial clinical challenges. Here’s a closer look at why its work matters: SPMS Progress: In an expanded access program, participants demonstrated improved fatigue levels and reduced brain inflammation, as measured by microglial activation. These are significant outcomes in a condition where effective therapies are limited. Alzheimer’s Disease: Preclinical studies have shown Foralumab’s ability to alleviate inflammation in the brain. With Phase 2 trials beginning in 2024, the therapy is positioned to offer a novel approach that complements existing treatments. What Sets Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) Apart A Unique Approach to Delivery: By choosing an intranasal delivery method, Tiziana ensures precise targeting of neuroinflammation with minimal systemic side effects. This is a pivotal advantage in managing chronic neurological conditions. Robust Data Supporting Its Platform: Published findings in the Proceedings of the National Academy of Sciences underscore Foralumab’s impact across multiple conditions, including SPMS and a recent global pan-demic. These results highlight its ability to regulate T-cell activity and reduce inflammation effectively. Experienced Leadership Driving Innovation: With Executive Chairman and Founder Gabriele Cerrone at the helm, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) benefits from a leadership team with deep expertise in dr-ug development. Cerrone’s history of guiding biotech firms to major milestones reinforces confidence in Tiziana’s trajectory. Potential Beyond the Current Pipeline: While SPMS and Alzheimer’s are the primary focuses, Foralumab’s mechanism of action points to broader applications across inflammatory and neurodegenerative diseases, setting the stage for further advancements. Key Milestones to Watch SPMS Phase 2a Progress: Ongoing trials are evaluating Foralumab’s efficacy and safety, with early data showing promising outcomes in reducing inflammation and improving symptoms. Alzheimer’s Phase 2 Launch: This trial will explore the therapy’s effects on microglial activity, a significant contributor to disease progression in Alzheimer’s. Expanded Research: Tiziana continues to explore additional indications where its intranasal anti-CD3 platform can make a meaningful difference. A Company Worth Watching Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is positioning itself as a leader in innovative therapies for neuroinflammatory and neurodegenerative diseases.  With groundbreaking science, proven leadership, and a clear focus on addressing critical medical challenges, this is a company making real strides in areas where effective solutions are desperately needed.  Tiziana Life Sciences, Ltd. (Nasdaq: TLSA)’s work stands as a testament to what’s possible when science and ingenuity converge. 7 Reasons Why Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) Is  Turning Heads Right Now… 1. Massive Market Growth Ahead: The neurodegenerative disease market is projected to more than double, growing from $52B in 2024 to over $102B by 2034, underscoring the demand for cutting-edge treatments like Foralumab. 2. Bullish Momentum Building: Tiziana Life Sciences (Nasdaq: TLSA) triggered 17 Bullish Signals on TradingView’s 30-minute timeframe yesterday, potentially signaling increasing attention from the public. 3. Revolutionary Delivery System: Foralumab, the only fully human anti-CD3 monoclonal antibody delivered intranasally, could redefine how complex diseases are addressed with precision and reduced side effects. 4. Prestigious Trial Expansion: Phase 2 SPMS clinical trials now include Yale, Johns Hopkins, and Cornell, boosting the credibility of Foralumab’s potential impact on secondary progressive multiple sclerosis. 5. Advancements in Alzheimer’s Research: The first patient with moderate Alzheimer’s disease has been successfully dosed at Brigham and Women’s Hospital, marking a critical step forward in addressing this devastating condition. 6. Featured in Nature Reviews Neurology: Foralumab earned recognition in one of the field’s leading scientific journals for its promise in conditions such as multiple sclerosis, Alzheimer’s, ALS, and Parkinson’s. 7. Potential in Metabolic Conditions: Beyond neurodegeneration, nasal anti-CD3 therapy has shown promise in addressing challenges linked to GLP-1 agonist discontinuation, such as muscle and bone loss. From 17 Bullish Signals on TradingView to groundbreaking advancements in neurodegenerative disease treatments, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) has all the makings of a standout company.  If I were you, I’d consider adding (TLSA) to your radar this week. Keep a look out for my next update. We have all eyes on (TLSA) right now. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 01/23/2025 and ending on 01/23/2025 to publicly disseminate information about (TLSA:US) via digital communications. Under this agreement, Media 1717 LLC has been paid an six thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (TLSA:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/tlsa/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice